Key Highlights

  • Shares were up 15.07 percent to USD 1.68 in pre-market trading on November 2, 2026.
  • No company announcement dated late October or November 2, 2026 was identified.
  • Cash and equivalents were USD 18.6 million as of June 30, 2026, with runway guided into the second half of 2027.
  • A one-for-five Reverse Stock Split took effect for trading on August 31, 2026.
  • Phase 1b proof-of-concept data for Auxora in pulmonary arterial hypertension is expected in mid-2027.

What Moved the Stock Before the Bell

CalciMedica (NASDAQ:CALC) was up 15.07 percent to USD 1.68 in pre-market trading on November 2, 2026. The company did not appear to have issued a press release or filing that explains the move, and none dated between late October and November 2, 2026 was identified.

Without a catalyst, the move looks more like momentum in a thinly traded, low-priced biotech share. This is a measured reading, not a confirmed cause.

Recent Company Developments

The latest dated updates come from the summer. On June 24, 2026 the company said the FDA had reviewed interim safety data from its Phase 2 KOURAGE acute kidney injury trial and provided no comments. The company said it does not plan to restart that trial at this time.

On July 29, 2026, it said the FDA aligned with the design of a Phase 2b acute pancreatitis trial. Starting that study depends on additional financing.

Business Background and Results

CalciMedica is a clinical-stage biotechnology company developing Auxora, an intravenous CRAC channel inhibitor, and CM5480, an oral preclinical candidate. Its focus has shifted to pulmonary hypertension, where it plans a Phase 1b study with data expected in mid-2027.

In its second quarter 2026 report, the company posted a net loss of USD 7.7 million, or USD 0.45 per share, and Research and Development expense of USD 2.1 million. Cash and equivalents were USD 18.6 million as of June 30, 2026.

Financing, Dilution and Listing Risks

On June 24, 2026, CalciMedica announced a private Placement of up to about USD 49 million, with about USD 15 million upfront. The units carried warrants that could add roughly USD 34 million if fully exercised, which creates dilution risk.

On August 27, 2026, it announced a one-for-five reverse split, saying the aim was to meet the Nasdaq minimum bid price requirement. As a Penny Stock with a small share count, CalciMedica can see sharp price swings, thin Liquidity and further dilution.

What to Watch Next

The third quarter results, due in November, should update cash and spending. Shareholders may also look for news on the pulmonary hypertension study start and any financing tied to the pancreatitis trial. Pre-market gains on light Volume often fade, so confirmation from company filings matters.